ArticleJournal of virology2005
Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 108 citations in OpenAlex.
- Article
- SARS-CoV-2 and Epstein-Barr Virus-like Particles Associate and Fuse with Extracellular Vesicles in Virus Neutralization Tests.Biomedicines · 2023Article
- Identification of nurse shark VFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Article
- IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes.Cell reports · 2022Article
- Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines.Antibodies (Basel, Switzerland) · 2022Review
- Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test.PNAS nexus · 2022Article
- Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.Microbiology spectrum · 2022Article
- Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.Current opinion in virology · 2022Review
- Pandemics and the English Language: Concepts Critical for Conversing About COVID-19.Pathogens & immunity · 2022Article
- Seroprevalence of anti-SARS-CoV-2 antibodies in Thai adults during the first three epidemic waves.PloS one · 2022Article
- Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand.BMC infectious diseases · 2021Article
- Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel.Seminars in immunology · 2021Review
- Animal and human RNA viruses: genetic variability and ability to overcome vaccines.Archives of microbiology · 2021Review
- Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy.Reviews in medical virology · 2021Review
- COVID-19 Vaccination: From Interesting Agent to the Patient.Vaccines · 2021Review
- Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses.Cell reports. Medicine · 2021Article
- COVID-19 vaccine: where are we now and where should we go?Expert review of vaccines · 2021Review
- Article
- Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.Frontiers in immunology · 2021Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spike (S) protein of the severe acute respiratory syndrome coronavirus (SARS-CoV) interacts with cellular receptors to mediate membrane fusion, allowing viral entry into host cells; hence it is recognized as the primary target of neutralizing antibodies, and therefore knowledge of antigenic determinants that can elicit neutralizing antibodies could be beneficial for the development of a protective vaccine. Here, we expressed five different fragments of S, covering the entire ectodomain (amino acids 48 to 1192), as glutathione S-transferase fusion proteins in Escherichia coli and used the purified proteins to raise antibodies in rabbits. By Western blot analysis and immunoprecipitation experiments, we showed that all the antibodies are specific and highly sensitive to both the native and denatured forms of the full-length S protein expressed in virus-infected cells and transfected cells, respectively. Indirect immunofluorescence performed on fixed but unpermeabilized cells showed that these antibodies can recognize the mature form of S on the cell surface. All the antibodies were also able to detect the maturation of the 200-kDa form of S to the 210-kDa form by pulse-chase experiments. When the antibodies were tested for their ability to inhibit SARS-CoV propagation in Vero E6 culture, it was found that the anti-SDelta10 antibody, which was targeted to amino acid residues 1029 to 1192 of S, which include heptad repeat 2, has strong neutralizing activities, suggesting that this region of S carries neutralizing epitopes and is very important for virus entry into cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.